Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | KEYNOTE-177: translating results for patients and clinicians

Kai-Keen Shiu, FRCP, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the importance of the results from KEYNOTE-177 (NCT02563002) for patients with bowel cancer, and their treating physicians, including the significance of determining whether tumors are microsatellite-instability high or mismatch repair deficient. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).


Honoraria from Bristol-Myers Squibb, Guardant Health, Innovent Biologics, Merck KGaA, Merck Sharp and Dohme, Roche

Consultant or Advisory Role from Merck Sharp and Dohme, Roche,

Research Funding from Bristol-Myers Squibb (Inst), Gilead Sciences (Inst), Merck KGaA (Inst), Merck Sharp and Dohme (Inst), Roche (Inst)

Travel, accommodations and expenses from Innovent Biologics, Merck KGaA, Roche